Europe’s benchmark EU Stoxx 50 index could be at risk of a near-term pullback as Pfizer slashes its vaccine production targets and the ECB tempers easing expectations.
<p>News from Monday on the SNB, which will not be paying profits to the government for the second year in a row. </p><p>The very strong CHF has outweighed capital gains from equity a
Leave a Comment